News
S*BIO Receives BioSingapore’s 2009 Award for the Most Successful Bio-Partnership in Asia
S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award
S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
S*BIO Announces a Collaboration with Onyx Pharmaceuticals worth up to US$550 Million
S*BIO Enters Research Collaboration with Tan Tock Seng Hospital for Therapeutic and Biomarker Evaluation of JAK2 Inhibitor SB1518
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
S*BIO Presents Clinical Data at the 20th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” Demonstrating Superior Profile of S*BIO’s Novel Anti-Cancer Drug SB939
S*BIO Completes US$26 Million Equity Financing
S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
S*BIO Oral JAK-2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and other Hematological Disorders
S*BIO Expands Pipeline with the Development of a Unique Flt3 – CDK Inhibitor as a Targeted Therapy for Acute Leukemias
S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
S*BIO Becomes Singapore's First Biotech Company to Initiate Clinical Trial of Novel Anti-Cancer Drug
S*BIO and National University Hospital-National University of Singapore Tissue Repository to Partner on Tumor Biomarker Research
S*BIO and A*STAR To Develop New Compounds To Treat Cancer
S*BIO Announces Research Collaboration with Karolinska Institutet
S*BIO Announces Incorporation of SBIO INC. and the Opening of US Operations
| |
Vision
S*BIO targets defined molecular pathways to inhibit the development of select tumour types, positioning us as a leader in oncology drug discovery research.
S*BIO translates a profound understanding of cancer biology into best-in-class clinical compounds, establishing us as a preferred partner and collaborator in the development of innovative cancer treatments.
S*BIO transforms the lives of people with cancer by creating breakthrough therapies with improved clinical outcomes, demonstrating our determination to be a driving force in the fight against cancer.
Programmes for Licensing
Click below for free downloads of our latest presentation(s)
Pipeline
| |
